Mariele Gatto1, Anna Ghirardello1, Roberto Luisetto2, Nicola Bassi1, Marny Fedrigo3, Marialuisa Valente3, Sonia Valentino4, Dorella Del Prete5, Leonardo Punzi1, Andrea Doria6. 1. Division of Rheumatology, Department of Medicine, University of Padova, Via Giustiniani 2, 35123, Padova, Italy. 2. Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy. 3. Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Via Giustiniani 2, 35123, Padova, Italy. 4. Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) -Humanitas Clinical and Research Center, 20089, Milan, Italy. 5. Division of Nephrology, Department of Medicine DIMED, Laboratory of Histomorphology and Molecular Biology of the Kidney, University of Padua, Via Giustiniani 2, 35123, Padua, Italy. 6. Division of Rheumatology, Department of Medicine, University of Padova, Via Giustiniani 2, 35123, Padova, Italy. Electronic address: adoria@unipd.it.
Abstract
BACKGROUND: Anti-pentraxin 3 (PTX3) antibodies were associated with the absence of lupus glomerulonephritis in humans. AIM: To explore the effects of anti-PTX3 antibodies in New Zealand Black/White (NZB/NZW F1) mice and their inherent mechanisms of action. MATERIALS AND METHODS: 30 NZB/NZW F1 mice were subdivided into 3 groups of 10 mice each and subcutaneously injected with PTX3, alum and PBS (group 1), alum and PBS (group 2) or PBS alone (group 3), 3 times 3 weeks apart, before development of renal disease. Mice were followed until natural death. Histological analysis and immunohistochemistry were performed on harvested kidneys. Effects of anti-PTX3 antibodies on C1q binding to immobilized PTX3-anti-PTX3 immune complexes were evaluated in vitro using human SLE sera. Qualitative characterization of human IgG anti-PTX3 was performed. RESULTS: Only group 1 mice developed anti-PTX3 antibodies. Anti-dsDNA and anti-C1q antibodies appeared significantly later and at lower levels in group 1 mice vs. controls (p < 0.0001). Proteinuria-free and overall survival were significantly increased in group 1 mice vs. controls (p < 0.05 and p = 0.03, respectively). Histopathological analysis showed that glomerular and tubular PTX3 staining and renal lesions were increased in controls compared with immunized mice. Addition of human SLE sera positive for anti-PTX3 antibodies to C1q and fixed PTX3 interfered with C1q binding to PTX3-anti-PTX3 immune complexes. Qualitative characterization of human IgG anti-PTX3 showed an increased proportion of IgG4. CONCLUSIONS: Anti-PTX3 antibodies delay lupus-like nephritis and prolong survival of NZB/NZW F1 mice. In vitro observations suggest anti-PTX3 antibodies may dampen complement activation via their Fc fragment, likely hindering renal inflammation.
BACKGROUND:Anti-pentraxin 3 (PTX3) antibodies were associated with the absence of lupus glomerulonephritis in humans. AIM: To explore the effects of anti-PTX3 antibodies in New Zealand Black/White (NZB/NZW F1) mice and their inherent mechanisms of action. MATERIALS AND METHODS: 30 NZB/NZW F1 mice were subdivided into 3 groups of 10 mice each and subcutaneously injected with PTX3, alum and PBS (group 1), alum and PBS (group 2) or PBS alone (group 3), 3 times 3 weeks apart, before development of renal disease. Mice were followed until natural death. Histological analysis and immunohistochemistry were performed on harvested kidneys. Effects of anti-PTX3 antibodies on C1q binding to immobilized PTX3-anti-PTX3 immune complexes were evaluated in vitro using humanSLE sera. Qualitative characterization of human IgG anti-PTX3 was performed. RESULTS: Only group 1 mice developed anti-PTX3 antibodies. Anti-dsDNA and anti-C1q antibodies appeared significantly later and at lower levels in group 1 mice vs. controls (p < 0.0001). Proteinuria-free and overall survival were significantly increased in group 1 mice vs. controls (p < 0.05 and p = 0.03, respectively). Histopathological analysis showed that glomerular and tubular PTX3 staining and renal lesions were increased in controls compared with immunized mice. Addition of humanSLE sera positive for anti-PTX3 antibodies to C1q and fixed PTX3 interfered with C1q binding to PTX3-anti-PTX3 immune complexes. Qualitative characterization of human IgG anti-PTX3 showed an increased proportion of IgG4. CONCLUSIONS: Anti-PTX3 antibodies delay lupus-like nephritis and prolong survival of NZB/NZW F1 mice. In vitro observations suggest anti-PTX3 antibodies may dampen complement activation via their Fc fragment, likely hindering renal inflammation.
Authors: L Wirestam; H Enocsson; T Skogh; M L Eloranta; L Rönnblom; C Sjöwall; J Wetterö Journal: Clin Exp Immunol Date: 2017-03-31 Impact factor: 4.330
Authors: Giuseppe A Ramirez; Patrizia Rovere-Querini; Miriam Blasi; Silvia Sartorelli; Maria Chiara Di Chio; Mattia Baldini; Rebecca De Lorenzo; Enrica P Bozzolo; Roberto Leone; Alberto Mantovani; Angelo A Manfredi; Enrico Tombetti Journal: Front Immunol Date: 2019-05-29 Impact factor: 7.561
Authors: Mariele Gatto; Annika Wiedemann; Nadja Nomovi; Karin Reiter; Eva Schrezenmeier; Thomas Rose; Franziska Szelinski; Andreia C Lino; Sonia Valentino; Anna Ghirardello; Thomas Dörner; Andrea Doria Journal: Front Immunol Date: 2019-01-25 Impact factor: 7.561
Authors: Irina A Pashnina; Irina M Krivolapova; Tamara V Fedotkina; Varvara A Ryabkova; Margarita V Chereshneva; Leonid P Churilov; Valeriy A Chereshnev Journal: Antibodies (Basel) Date: 2021-02-25
Authors: Mariele Gatto; Roberto Luisetto; Anna Ghirardello; Laura Cavicchioli; Gaia Codolo; Alessandra Biasiolo; Giuseppe Maggioni; Francesca Saccon; Marianna Beggio; Andrea Cappon; Roberta Venturini; Patrizia Pontisso; Andrea Doria Journal: Front Immunol Date: 2018-09-11 Impact factor: 7.561